Allianz Asset Management’s Keros Therapeutics KROS Stock Holding History

Allianz Asset Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,400	Closed	-$604K	–	2278
2024 Q3	$604K	Buy	10,400 +1,500	+17%	+$74.1K	﹤0.01%	1807
2024 Q2	$407K	Hold	8,900	–	–	﹤0.01%	1899
2024 Q1	$589K	Buy	+8,900	New	+$528K	﹤0.01%	1568
2023 Q4	–	Sell	-12,200	Closed	-$389K	–	2193
2023 Q3	$389K	Hold	12,200	–	–	﹤0.01%	2011
2023 Q2	$490K	Hold	12,200	–	–	﹤0.01%	1748
2023 Q1	$521K	Sell	12,200 -4,000	-25%	-$202K	﹤0.01%	1893
2022 Q4	$778K	Sell	16,200 -2,000	-11%	-$93.4K	﹤0.01%	1599
2022 Q3	$685K	Sell	18,200 -110,077	-86%	-$3.82M	﹤0.01%	1483
2022 Q2	$3.54M	Buy	128,277 +52,886	+70%	+$2.32M	﹤0.01%	1219
2022 Q1	$4.1M	Buy	75,391 +27,544	+58%	+$1.41M	﹤0.01%	1301
2021 Q4	$2.79M	Buy	+47,847	New	+$2.39M	﹤0.01%	1478

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Allianz Asset Management's KROS Position: Q4 2024 in Review

Allianz Asset Management sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 10,400 shares — an estimated $604K sold.

Allianz Asset Management first reported a position in KROS in Q4 2021 and held it in 11 quarters. The position peaked at $4.1M in Q1 2022. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

Allianz Asset Management reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
Allianz Asset Management sold 10,400 Keros Therapeutics shares in Q4 2024, an estimated $604K.
Allianz Asset Management first reported a position in Keros Therapeutics in Q4 2021 and held it in 11 quarters.
Allianz Asset Management's Keros Therapeutics position peaked at $4.1M in Q1 2022.
161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on Allianz Asset Management's 13F filing for Q4 2024, filed 3 Feb 2025.